Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐ CAR ‐T‐cell therapy
British Journal of Haematology · 2025-09 · 207 (3) · 1002-1010
DOI: 10.1111/bjh.20266 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 09.07.2025. Verfasst von Tomoyasu Jo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Cell Proliferation, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Efficacy of chimeric antigen receptor (CAR) T‐cell therapy hinges on CAR‐T potency, as well as on tumour traits and disease status. Potency assessment currently relies on post‐infusion in vivo growth; therefore, manufacturing metrics could provide early potency predictions, enabling potency‐guided strategies. To assess the impact of ex vivo cell growth during manufacturing on clinical outcomes, we analysed diffuse large B‐cell lymphoma patients treated with tisagenlecleucel, merging clinical records with manufacturing parameters. Of 75 cases, 21 (28%) showed poor growth, indicated by any decrease in cell number during manufacturing. Good growth correlated with significantly better overall response rate (85.2% vs. 52.4%; p = 0.006), with enhanced lymphocyte increase in peripheral blood after infusion. Multivariate analysis revealed that this group had significantly higher progression‐free survival (PFS) (adjusted hazard ratio [aHR]: 0.377; 95% confidence interval [CI]: 0.180–0.789; p = 0.010) and overall survival (OS) (aHR: 0.191; 95% CI: 0.071–0.510; p = 0.001), with lower cumulative incidence of disease progression (aHR: 0.412; 95% CI: 0.198–0.858; p = 0.018), compared to the poor growth group, even after adjusting for clinical factors, bridging therapies performed between apheresis and infusion and disease status at infusion. Our findings suggest that good cell growth during manufacturing predicts favourable post‐CAR‐T outcomes. Identifying clinical factors that influence manufacturing parameters could improve post‐CAR‐T outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
- Department of Cytotherapy, Kyoto University Hospital, Kyoto, Japan.
- Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Junya Kanda, Momoko Nishikori
Zitieren
APA
Jo, T., Arai, Y., Shimizu, T., Kitawaki, T., Sakamoto, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., & Takaori-Kondo, A. (2025). Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐ CAR ‐T‐cell therapy. British Journal of Haematology, 207(3), 1002-1010. https://doi.org/10.1111/bjh.20266
Vancouver
Jo T, Arai Y, Shimizu T, Kitawaki T, Sakamoto T, Mizumoto C, et al. Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐ CAR ‐T‐cell therapy. British Journal of Haematology. 2025;207(3):1002-1010. doi:10.1111/bjh.20266
BibTeX
@article{Jo2025,
author = {Jo, Tomoyasu and Arai, Yasuyuki and Shimizu, Tomoshige and Kitawaki, Toshio and Sakamoto, Takashi and Mizumoto, Chisaki and Kanda, Junya and Nishikori, Momoko and Yamashita, Kohei and Nagao, Miki and Takaori-Kondo, Akifumi},
title = {Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐ CAR ‐T‐cell therapy},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {3},
pages = {1002--1010},
doi = {10.1111/bjh.20266}
}
EUVIMED